Similar articles

• [Adriamycin/cyclophosphamide: current standard in the adjuvant therapy of breast carcinoma? Or: how should one really put this question?].

  Cavalli F. Cavalli F. Schweiz Med Wochenschr. 1994 Oct 29;124(43):1882-4. Schweiz Med Wochenschr. 1994. PMID: 7973514 Clinical Trial. German. No abstract available.
• Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.

  Mathé G, Misset JL, Plagne R, Reizenstein P, Belpomme D, Le Mevel B, Guerrin J, Fumoleau P, Metz R, Delgado M, et al. Mathé G, et al. Drugs Exp Clin Res. 1986;12(1-3):143-5. Drugs Exp Clin Res. 1986. PMID: 3525068 Clinical Trial.
• Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.

  Mikhak B, Zahurak M, Abeloff MD, Fetting JH, Davidson NE, Donehower RC, Waterfield W, Kennedy MJ. Mikhak B, et al. Cancer. 1999 Feb 15;85(4):899-904. Cancer. 1999. PMID: 10091768 Clinical Trial.
• The use of mitoxantrone in the treatment of breast cancer.

  Hainsworth JD. Hainsworth JD. Semin Oncol. 1995 Feb;22(1 Suppl 1):17-20. Semin Oncol. 1995. PMID: 7863347 Review. No abstract available.
• Recent progress in breast cancer management. Combined modality (adjuvant) therapy.

  Cowan K, Lippman M. Cowan K, et al. Arch Intern Med. 1981 Jul;141(8):1055-9. Arch Intern Med. 1981. PMID: 7018440 Review. No abstract available.